• About
    • Leadership
  • Therapeutic Focus
    • UbiPro™ Platform
    • PROTAC
    • Therapeutic Areas
  • Partnering
    • The Progenra Advantage
    • Partnering Opportunities
    • Investor Relations
    • Collaborations
  • Careers
    • R&D, Biology
    • R&D, Medicinal Chemistry
  • News
    • News
    • Meetings
    • Publications
  • Blog

Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.

by Progenra | May 26, 2020 | Blog

May 2020. Progenra has received new funding for its Michael J. Fox Foundation Therapeutic Pipeline Award, Discovery and Development of Novel Parkin Activators. Progenra’s novel Parkin activator molecules are undergoing preclinical development, and this funding will...

Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.

by Progenra | May 26, 2020 | Blog

February 2020. Ubiquitin-specific proteases (USPs), the major class of deubiquitinating enzymes, or DUBs, remove conjugated ubiquitin from proteins in cells and in so doing help to regulate the content, location, or activity of the target protein. Approximately 80...

Characterization of Selective Covalent inhibitors of USP7- AACR Poster

by Progenra | May 15, 2019 | Blog

Abstract- The ubiquitin-specific protease 7 (USP7) has emerged as an attractive antitumor target due to its critical roles in several cancer signaling pathways as well as its essential role in maintaining Foxp3+ T-regulatory cell (Treg) functions. Pharmacological...

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

by Progenra | May 15, 2019 | Blog

Abstract- There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular...

Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch

by Progenra | May 14, 2019 | Blog

Abstract – Protein ubiquitination is an important means of post-translational modification which plays an essential role in the regulation of various aspects of leukocyte development and function. The specificity of ubiquitin tagging to a protein substrate is...
« Older Entries

Recent Posts

  • Progenra and the Frederick National Laboratory for Cancer Research Establish a contractor Cooperative Research and Development Agreement (cCRADA) to Develop KRAS Degraders for Cancer Therapy
  • Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
  • Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.
  • Characterization of Selective Covalent inhibitors of USP7- AACR Poster
  • Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Archives

  • February 2022
  • May 2020
  • May 2019
  • December 2018
  • April 2018
  • March 2018
  • September 2017
  • June 2017
  • May 2017
  • December 2016
  • December 2015
Progenra Logo

Contact

  610.644.6974
  610.644.8616
   271A Great Valley Parkway
      Malvern PA, 19355

For More Information

  info@progenra.com
  bd@progenra.com
      (Business Development inquries)
  • Facebook
  • Twitter
  • LinkedIn
© 2023 Progenra Inc. All Rights Reserved.
Website by eNet Web Services